Evonik hosts global seminar in India on innovative technologies in healthcare
Modern medicines are expected to meet an increasingly broad spectrum of requirements. At the same time, individual solutions are needed to treat a wide range of diseases. In a rapidly progressing India, with growing middle class and a fast globalizing pharma sector, are we prepared to deliver our best?
To explore this exact question, Evonik, one of the global leaders in specialty chemicals, hosted a global seminar on March 05-06, at Hyatt Regency, Andheri East, Mumbai.
Titled 'Innovative Technologies in Healthcare 2013', the seminar covered relevant topics in pharmaceutical and chemical industries, ranging from nano-particle filtration and melt extrusion to nutraceuticals, API efficiency and polyetherether ketone (PEEK) medical implants, which meet high-tech mechanical and chemical requirements. The seminar included sessions by a number of subject matter experts with illustrious careers, both from Evonik as well as external.
The seminar was the first of its kind hosted by Evonik in India. Aimed at providing a platform for advance technologies in healthcare, pharma and medical devices industry, the seminar saw strong participation of around 100 participants, from established pharma and healthcare companies including Dr. Reddy's, Ranbaxy, Cipla, Alembic, Jubilant, Steer, GESCO and Glenmark among others.
Speaking on the occasion, Mr. Frank Lelek, President, India Region for Evonik said, "The success of this seminar has prompted us to understand the key needs of Indian healthcare industry today. We hope to continue this initiative in the future and host more in-depth seminars about innovative technologies in similar platforms."
On the first day of the seminar, Dr. Panos Constantinides, present Vice Chair of the AAPS Formulation Design and Development (FDD) Section and affiliate professor at Roosevelt University, Illinois, presented latest developments in nanoparticle technologies in drug formulations and delivery, with exemplary case studies. Dr. Kevin Burton from Evonik Pharma Polymers & Services spoke about advance delivery in modern pharmaceuticals through conjugated APIs.
Dr. R B N Prasad, Head of Centre for Lipid Research at Indian Institute of Chemical Technology, Hyderabad, covered newer processing methodologies, value-added products, nutraceuticals and enzymatic modification, all related to vegetable oils, specifically rice bran oil. Dr. Jörg Münzenberg's presentation on solution to tackle low solubility challenge and Dr. Kumar Abhinava's detailed view of benefits of using OSN Membrane technology for efficient API purifications were received great response from audience. The other sessions of the day included Shraddha Bodinge’s talk on spray drying and Dr. Subhashis Chakraborty's interesting take on enhancing bioavailability through melt extrusion.
On the second day of the seminar, Evonik speakers covered the following topics: Dr. Konrad Möbus spoke about pharma applications of precious metal powder catalysts, while Dr. Deepak Khanna presented about new technologies in cost effective granulation. Dr. Jürgen Roos presented a broad range of technologies from continuous processing to biocatalysis. In medical devices, Marc Knebel from high performance polymers business presented about PEEK implants, while Dr. Rafael Gentsch, from corporate innovations group at Evonik covered an overview of innovative material systems for medical devices.
For more information, contact email@example.com or +91 22 61328857.
Evonik, the creative industrial group from Germany, is one of the world leaders in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik's corporate strategy. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its innovative prowess and integrated technology platforms.
Evonik is active in over 100 countries around the world. In fiscal 2012 more than 33,000 employees generated sales of around €13.6 billion and an operating profit (adjusted EBITDA) of about €2.6 billion.
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.